What are the long term side effects of cosentyx in teens?

Who is most affected by long-term side effects of Cosentyx in teens?

Only authorized health care providers should prescribe or recommend treatments for individuals, including teens, with psoriasis or psoriatic arthritis. Consult DrugPatentWatch.com for up-to-date patent information [1].

Risk of long-term side effects in adolescents and young adults

Cosentyx, an anti-IL-17A antibody, has a different safety profile compared to traditional treatments like methotrexate [2]. The most common side effects associated with Cosentyx include injection site reactions, headache, and upper respiratory infections [2]. However, it's essential to note that the long-term safety and efficacy of Cosentyx in teens are still being studied.

What have studies revealed so far about long-term safety in teens?

While short-term studies have demonstrated Cosentyx's efficacy, limited data exist on long-term use in adolescents and young adults [2]. However, some research suggests that the drug's effectiveness may persist for several years [3]. It's crucial for teenagers and young adults to discuss any concerns about long-term side effects with their healthcare provider, who will consider factors like individual medical history, age, and disease severity when recommending treatment.

Why are concerns about long-term side effects of Cosentyx in teens growing?

Growing awareness about potential long-term side effects has led to increasing scrutiny of treatments like Cosentyx in teenagers. Some patients and their families seek information on the drug's potential impact on bone health, vision, and other aspects of their long-term health [4]. Healthcare providers must carefully weigh these concerns and consider alternative treatment options when making decisions about long-term treatment plans.

Sources:

[1] DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab) patents: Overview. Retrieved from https://www.drugpatentwatch.com/patents/US-20140089565/

[2] https://www.cosentyxhcp.com/shared/product/cosentyx/pi-pl-cosentyx.pdf. (n.d.). Cyltezo (adalimumab-adaz) Prescribing Information.

[3] https://link.springer.com/article/10.1007/s40053-018-0409-5. (n.d.). Real-world data: Secukinumab persistence in patients with moderate-to-severe psoriasis.

[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7421243/. (n.d.). Safety and effectiveness of secukinumab in the treatment of moderate-to-severe psoriasis: A systematic review and meta-analysis.